Novo Nordisk ($NOVO B (+1,26 %)), the maker of Ozempic and Wegovy, just lost most of its value.
From a peak near €130
Now trading around €42
That’s more 50% collapse...
And five years of investor growth erased instantly
Imagine riding the hype:
“Everyone wants Ozempic.”
“Weight loss is the next trillion-dollar market.”
“Nothing can stop Novo.”
Then—boom.
$70–90 billion in market cap gone.
The Trap of Trend-Driven Investing
Most people chased the headlines, not the fundamentals:
“Best-performing pharma stock”
“Can’t lose with obesity drugs”
“Just follow the momentum”
Trends Fade. Cash Flow Stays.
Buffett said it best:
“Only when the tide goes out do you discover who’s been swimming naked.”
Novo wasn’t just naked—
It was dragged under by overexposure, overhype, and unmet expectations.
The Takeaway?
If you’re still buying stocks just because they’re trending…
Ask yourself:
What protects your portfolio when the hype dies?
What pays you when prices collapse?
